BioCardia heads into the post-earnings stretch with short sellers in retreat and a CEO who keeps buying despite a week of heavy selling pressure.
The week was shaped by Thursday's Q1 print. BioCardia missed the EPS estimate by $0.04, reporting $(0.21) against a $(0.17) consensus. The stock dropped 7.3% on the day and closed Friday at $1.01 — down 9% on the week and 14% over the past month. Against that backdrop, however, the earnings call carried a notable catalyst: management outlined a Japan Shonin filing for CardiAMP within roughly seven months, targeting a ~19-month path to approval. That regulatory runway, alongside an FDA alignment on the Helix catheter clearance pathway announced the previous week, gave the bulls something to hold onto even as the headline number disappointed.
Short interest this week tells a more complicated story than it first appears. It surged nearly 190% week-on-week to 4.2% of the free float — but the build peaked on May 8 at nearly 968,000 shares, then unwound sharply through the earnings date to roughly 441,000 shares by May 14. The spike and reversal look more like a tactical trade around the earnings event than a structural shift in sentiment. The borrow market reflects that: cost to borrow is a modest 1.45% — elevated from its April lows but not restrictive — and borrow availability remains loose. Utilization, which hit 69% on May 8 at the peak of the short build, has since pulled back to about 23%, well below the 52-week high of 96%. There is no meaningful squeeze pressure in the lending market right now.
CEO Peter Altman has been an uninterrupted presence on the buy side. His most recent purchase was on April 29 — 5,000 shares at $1.11 — and he has executed at least nine separate open-market buys since December 2025, accumulating around 11,900 net shares over the past 90 days at an average near $1.14. The total dollar value is small (roughly $13,500), but the consistency is notable for a micro-cap in clinical-stage development. He now holds just over 280,000 shares, or roughly 2.6% of the company.
Analyst coverage remains thin and dated. HC Wainwright's Joseph Pantginis last reiterated his Buy with a $25 target in September 2025 — a level that implies more than 2,000% upside from the current price. Given the distance between that target and Friday's close of $1.01, readers should treat the figure as a long-dated optionality call on regulatory success rather than a near-term valuation anchor. No recent changes from any other firm are on record. The ORTEX short score settled at 48 on May 14, down sharply from a reading of 74 at the May 8 peak — consistent with the unwinding of the short position after the event.
Closer peers had a rough week in sympathy. RXRX dropped nearly 12% over the five sessions and PRME fell about 8.7%, suggesting sector-wide pressure on small-cap biotech rather than a BCDA-specific selloff. CCCC was the notable outlier, gaining almost 21% on the week — a reminder of how idiosyncratic catalysts can diverge sharply within the peer group.
What to watch next: BioCardia has flagged a Q1 2026 Japan Shonin filing timeline, and the FDA's Helix catheter pathway decision remains the nearest binary for the stock. The next scheduled earnings event is in August, leaving the regulatory calendar as the primary driver between now and then.
See the live data behind this article on ORTEX.
Open BCDA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
